What type of study is this?

This is a Pre-Registered Trial study.

What question did this study set out to answer?

This research investigates the efficacy and safety of selinexor combinations in MDS/MPN overlap syndromes.

December 8, 2025BloodOpen Access

Selinexor in combination with azacitidine or Ruxolitinib for Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Multi-Center Prospective Exploratory Study

View Full Paper

Ask AI

Bookmark

Authors

ZLZiwei Liu JZJunling Zhuang NWNa Wei

Discussion

Member takes

Overview

Prospective exploratory trial shows efficacy of selinexor combinations in myelodysplastic/myeloproliferative neoplasms, indicating safety with manageable adverse events.

Key Points

This research investigates the efficacy and safety of selinexor combinations in MDS/MPN overlap syndromes.
Conducted a prospective exploratory single arm trial.
Evaluated efficacy and safety of selinexor with azacitidine or ruxolitinib.
Primary endpoint was overall response rate at six months, using 2015 IWG criteria.
Overall response rate at six months was 60% for the cohort.
MDS-dominant group had an ORR of 75%.
MPN-dominant group showed an ORR of 56.3% with partial responses in 12.5%.
70% of patients experienced adverse events, with 15% having grade ≥3 AEs.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236cfb1 https://doi.org/10.1182/blood-2025-5624

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

Selinexor in combination with azacitidine or Ruxolitinib for Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Multi-Center Prospective Exploratory Study

View Full Paper

Ask AI

Bookmark

Authors

ZLZiwei Liu JZJunling Zhuang NWNa Wei

Discussion

Member takes

Overview

Prospective exploratory trial shows efficacy of selinexor combinations in myelodysplastic/myeloproliferative neoplasms, indicating safety with manageable adverse events.

Key Points

This research investigates the efficacy and safety of selinexor combinations in MDS/MPN overlap syndromes.
Conducted a prospective exploratory single arm trial.
Evaluated efficacy and safety of selinexor with azacitidine or ruxolitinib.
Primary endpoint was overall response rate at six months, using 2015 IWG criteria.
Overall response rate at six months was 60% for the cohort.
MDS-dominant group had an ORR of 75%.
MPN-dominant group showed an ORR of 56.3% with partial responses in 12.5%.
70% of patients experienced adverse events, with 15% having grade ≥3 AEs.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236cfb1 https://doi.org/10.1182/blood-2025-5624

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark